VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ARDT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ARDTArdent Health Inc.
$14.40$2.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ARDT
  4. Financial Ratios

Ardent Health Inc. (ARDT) Financial Ratios

Latest Ratios: P/E Ratio 14.0x · EV/EBITDA 7.4x · ROE 8.5%. (2016–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ARDT Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2018FY 2017FY 2016
Market Cap$2.1B$1.2B$2.3B—————
Enterprise Value$3.6B$2.8B$4.0B—————
P/E Ratio →13.959.2010.81—————
P/S Ratio0.320.200.38—————
P/B Ratio1.210.741.49—————
P/FCF7.354.8317.78—————
P/OCF4.392.657.20—————

P/E links to full P/E history page with 30-year chart

ARDT EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2018FY 2017FY 2016
EV / Revenue—0.440.67—————
EV / EBITDA7.385.837.23—————
EV / EBIT11.128.219.31—————
EV / FCF—10.8431.31—————

ARDT Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2018FY 2017FY 2016
Gross Margin97.5%97.5%82.7%97.4%81.4%100.0%100.0%100.0%
Operating Margin5.1%5.1%6.8%4.2%4.2%3.6%4.1%4.0%
Net Profit Margin2.1%2.1%3.5%0.9%3.7%-3.4%-1.2%0.7%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2018FY 2017FY 2016
ROE8.5%8.5%16.2%4.7%21.4%-19.4%-6.2%3.7%
ROA2.7%2.7%4.2%1.0%5.0%-5.6%-2.1%1.3%
ROIC7.5%7.5%9.7%5.7%6.6%6.3%8.4%11.7%
ROCE7.9%7.9%10.0%5.6%7.0%7.5%9.3%11.2%

ARDT Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2018FY 2017FY 2016
Debt / Equity1.341.341.502.212.271.771.250.61
Debt / EBITDA4.714.714.136.476.724.304.121.54
Net Debt / Equity—0.921.131.811.841.691.160.37
Net Debt / EBITDA3.233.233.135.295.444.103.810.95
Debt / FCF—6.0113.5323.24———40.82
Interest Coverage6.196.196.543.204.800.941.722.65

ARDT Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2018FY 2017FY 2016
Current Ratio1.971.971.941.631.741.381.451.44
Quick Ratio1.851.851.821.521.611.241.291.29
Cash Ratio0.680.680.590.440.560.100.140.28
Asset Turnover—1.201.201.061.061.521.261.94
Inventory Turnover1.311.318.981.348.91———
Days Sales Outstanding—39.6045.4653.0243.5446.4055.1845.26

ARDT Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2018FY 2017FY 2016
Dividend Yield————————
Payout Ratio————92.5%———

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2018FY 2017FY 2016
Earnings Yield7.2%10.9%9.3%—————
FCF Yield13.6%20.7%5.6%—————
Buyback Yield0.0%0.0%0.0%—————
Total Shareholder Yield0.0%0.0%0.0%—————
Shares Outstanding—$141M$133M$143M$143M$141M$141M$141M

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Thin margins amid leverage

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Discount Multiples Price Limited Earnings Growth

Based on the supplied multiples, ARDT trades at 17.63 trailing P/E and 8.48 EV/EBITDA, a modest premium to CHS-style distressed peers but a discount to HCA's 16.22 P/E and 10.04 EV/EBITDA, suggesting the market prices steady rather than accelerating earnings.

The forward P/E of 19.29 sits above the trailing figure, which implies consensus expects earnings to be lower or flat, not expanding, over the next year. Relative to HCA, the lower EV/EBITDA is consistent with a smaller scale and thinner operating margin of 5.15%, though it should not be read as a clean value signal given the quarterly EPS misses. The P/S of 0.40 and P/FCF of 9.29 look inexpensive, but these multiples rest on free cash flow that the quarterly series shows to be volatile and working-capital dependent.

Gross Margin Reflects Classification, Not Pricing Power

ARDT's reported gross margin swung from roughly 83% in 2025 to 15.9% in 2026Q3, while its net margin of 2.1% and operating margin of 5.1% indicate that true earning power sits well below headline levels.

The collapse in gross margin across quarters appears driven by changes in how clinical labor and supply costs are classified rather than by a shift in pricing, so gross margin is not a reliable basis for comparison here. Operating margin of 5.1% and net margin of 2.1% are the more informative measures, and both sit below HCA's 9.0% net margin and UHS's 8.6%. The gap to peers suggests limited room to absorb further wage inflation or reductions in supplemental government payments.

Returns Decaying Toward Cost of Capital

Based on reported figures, ARDT's ROIC has moved within a 1% to 3% band in recent quarters, and its ROE of 2.5% in 2026Q3 compares with 19.3% for UHS and 32.1% for Tenet, indicating weak capital compounding.

The ROIC trajectory from 8.0% in 2024Q4 to 2.2% in 2026Q3 suggests returns on invested capital have decayed as margins compressed, and the rising equity base has diluted ROE further. Compared with UHS at 12.3% ROIC and HCA at 19.9%, ARDT's returns look structurally lower rather than temporarily depressed. Investors should monitor whether margin recovery can lift ROIC back above the sector range.

Deleveraging Through Equity Rebuild, Not Debt Paydown

According to the reported balance sheet, debt-to-equity fell from 1.93 to 1.27 over eight quarters while total debt held near $2.3B, and debt-to-EBITDA of 16.61 in 2026Q3 remains elevated.

The improvement in leverage ratios reflects equity expansion rather than debt reduction, which means the absolute debt burden is unchanged against a thin 5.15% operating margin. Interest coverage of 6.29 in 2026Q3 is adequate but volatile, having ranged from 1.18 to 11.65 across the period, which suggests debt service comfort depends heavily on the quarter. Refinancing and covenant sensitivity warrant monitoring given the flat debt level.

Liquidity Holds Steady Under Current Ratios

Based on ARDT's reported figures, the current ratio of 2.13 and quick ratio of 2.03 in 2026Q3 indicate short-term obligations are comfortably covered, with cash rising to $766.2M over the period.

Because inventory days are low at 8 and the quick ratio nearly matches the current ratio, liquidity does not depend on inventory conversion. The strengthening cash buffer suggests near-term solvency is not the primary concern. Under severe stress, however, the more relevant constraint is the reliance on working-capital inflows to support free cash flow rather than the current ratio itself.

Misapplied Gross Margin Obscures True Earnings

The gross margin is the ratio most commonly misapplied to ARDT, as its swing from 83% to 15.9% reflects cost reclassification rather than economics, and operating margin of 5.1% better reflects earning power.

Applying gross margin comparisons against non-healthcare industries or against peers reporting clinical labor differently would produce misleading conclusions about pricing power. Analysts should normalize by reclassifying clinical labor into cost of sales, then evaluate operating margin, EBITDA conversion, and SWB expense trends. Investors should monitor whether the ratio gap to HCA and UHS narrows once normalized.

Download Financial Ratios Data

Includes 30+ ratios · 7 years · Updated daily

Consensus & Technical Research Suite
Open ARDT Terminal

ARDT Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ARDT — Frequently Asked Questions

Quick answers to the most common questions about buying ARDT stock.

What is Ardent Health Inc.'s P/E ratio?

Ardent Health Inc.'s current P/E ratio is 14.0x. The historical average is 10.0x. This places it at the 100th percentile of its historical range.

What is Ardent Health Inc.'s EV/EBITDA?

Ardent Health Inc.'s current EV/EBITDA is 7.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.5x.

What is Ardent Health Inc.'s ROE?

Ardent Health Inc.'s return on equity (ROE) is 8.5%. The historical average is 4.1%.

Is ARDT stock overvalued?

Based on historical data, Ardent Health Inc. is trading at a P/E of 14.0x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Ardent Health Inc.'s profit margins?

Ardent Health Inc. has 97.5% gross margin and 5.1% operating margin.

How much debt does Ardent Health Inc. have?

Ardent Health Inc.'s Debt/EBITDA ratio is 4.7x, indicating high leverage. A ratio above 4x may signal elevated financial risk.